Speeding Up Cellular Immunotherapy

New ‘off the shelf’ CAR T product shows promise in phase 1 study

Bridging Therapy Not Recommended for All CAR T Patients

New data presented by Moffitt shows poorer outcome for patients who receive bridging therapy prior to CAR T-cell therapy.

Together We Will (Fight Cancer)

Alexandra Buchanan started a Miles for Moffitt team last year while her dad was in treatment for non-Hodgkin lymphoma

Breakthroughs Running on Miles for Moffitt Grant

Funding builds momentum to continue critical cancer research.

Do You Know Your Lymphomas?

Lymphoma comes in different types and the most recognizable forms tend to include the name Hodgkin.

No U.S. Ban Yet on Textured Breast Implants

FDA says more data needed before banning implants associated with rare cancer.

New Cases Reported in Rare Breast Implant Linked Cancer

Breast implants can increase the risk of developing anaplastic large cell lymphoma

Nearly 40 Percent of CAR T Patients Remain in Remission

Many ZUMA-1 participants remain in remission and more than half of those treated remain alive.

New Study Shows CAR T-cell Therapy for Lymphoma Lives up to its Press

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data

Endeavor